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Objective: The Janssen Autism Knowledge Engine (JAKE®) is a clinical research
outcomes assessment system developed to more sensitively measure treatment
outcomes and identify subpopulations in autism spectrum disorder (ASD). Here we
describe JAKE and present results from its digital phenotyping (My JAKE) and biosensor
(JAKE Sense) components.
Methods: An observational, non-interventional, prospective study of JAKE in
children and adults with ASD was conducted at nine sites in the United States.
Feedback on JAKE usability was obtained from caregivers. JAKE Sense included
electroencephalography, eye tracking, electrocardiography, electrodermal activity, facial
affect analysis, and actigraphy. Caregivers of individuals with ASD reported behaviors
using My JAKE. Results from My JAKE and JAKE Sense were compared to traditional
ASD symptom measures.
Results: Individuals with ASD (N =144) and a cohort of typically developing (TD)
individuals (N = 41) participated in JAKE Sense. Most caregivers reported that overall
use and utility of My JAKE was “easy” (69%, 74/108) or “very easy” (74%, 80/108). My
JAKE could detect differences in ASD symptoms as measured by traditional methods.
The majority of biosensors included in JAKE Sense captured sizable amounts of quality
data (i.e., 93–100% of eye tracker, facial affect analysis, and electrocardiogram data
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was of good quality), demonstrated differences between TD and ASD individuals, and
correlated with ASD symptom scales. No significant safety events were reported.
Conclusions: My JAKE was viewed as easy or very easy to use by caregivers
participating in research outside of a clinical study. My JAKE sensitively measured a
broad range of ASD symptoms. JAKE Sense biosensors were well-tolerated. JAKE
functioned well when used at clinical sites previously inexperienced with some of the
technologies. Lessons from the study will optimize JAKE for use in clinical trials to
assess ASD interventions. Additionally, because biosensors were able to detect features
differentiating TD and ASD individuals, and also were correlated with standardized
symptom scales, these measures could be explored as potential biomarkers for ASD
and as endpoints in future clinical studies.
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT02668991 identifier:
NCT02668991
Keywords: autism spectrum disorder (ASD), biosensor, web and mobile application, mood report, assessment
INTRODUCTION
Widely accepted, standardized tools for diagnosing autism
spectrum disorder (ASD) include the Autism Diagnostic
Observation Schedule, 2nd edition (ADOS-2) and the Autism
Diagnostic Interview-Revised (Falkmer et al., 2013). However,
physiological and psychological instruments designed to detect
change over time in core and associated symptoms of ASD
are lacking. As ASD is a neurodevelopmental disorder with
its roots in brain structure and function, it is reasonable that
physiological and psychological measurements that assess this
structure and function would be useful. In addition, monitoring
of ASD symptoms in naturalistic settings will likely both improve
care of people with ASD and yield insights into the condition.
Such tools are needed to address significant unmet medical
needs for improved diagnosis and expanded treatment options
in ASD, and to develop novel therapies that target core and
associated symptoms.
Global efforts to identify potential biomarkers for use in
ASD research have been noted in the European Union (EU)
and US. The EU-AIMS initiative consists of a large public-
private partnership between academia, pharma, and foundations
(Loth et al., 2016) to carry out several large-scale studies
involving children, adolescents, and adults. In the US, the Autism
Biomarkers Consortium Clinical Trial (ABC-CT) is engaged
in a similar effort to examine change over time in a younger
cohort of children and adolescents with ASD (McPartland,
2018). These large-scale consortia utilize a select group of expert
academic sites and employ high-density tools (e.g., 128 lead
electroencephalogram [EEG] and magnetic resonance imaging)
to help identify biomarkers to stratify subgroups of individuals
with ASD that might be more responsive to a particular therapy,
and to measure change in symptoms and behavior over time.
Biomarker Development in ASD
Biosensor research is relatively new in its development and
application to ASD. Sensor-based biomarkers (e.g., EEG and
eye tracking) have the potential to measure progress objectively
and facilitate development of novel therapies for ASD core
and associated symptoms (Murias et al., 2018). Biomarkers
may be used to characterize participants who share common
pathophysiology, as well as being an objectivemeasure for clinical
outcomes (Loth et al., 2017).
Wearable Biosensors
Actigraphy
An actigraph measures physical activity and can be worn
on a participant’s wrist like a watch. Data recorded during
the day can be used to identify time periods of sedentary,
light, moderate, and moderate-to-vigorous activity. An ASD
population is expected to spend more time engaged in sedentary
activity, less time exposed to ambient light, and less moderate
and moderate-to-vigorous activity than typically developing
(TD) children of the same age (Vaughan Van Hecke et al.,
2009). Additionally, it has been reported that sleep problems
occur in ∼50–80% of children with ASD, compared with
9–50% for a TD group (Richdale and Schreck, 2009). The
use of actigraphy for sleep monitoring, with ∼90% sensitivity
of sleep estimation using curated data approaches, provides
a valid, more tolerable, and efficient potential alternative to
polysomnography (PSG) (Meltzer et al., 2012). Although PSG,
of course, remains the gold-standard for sleep measurements,
we feel the far greater versatility and practicality of actigraphy
makes it a reasonable choice for use in clinical studies. The
ability to automatically detect repetitive motor movements using
actigraphy and machine learning has also been demonstrated
(Goodwin et al., 2011, 2014; Großekathöfer et al., 2017).
Electrodermal Activity
ASD is partially characterized by sensory differences and atypical
affective responses, symptoms included in standard diagnostic
tools such as the ADOS-2 (Lord et al., 2012), Autism Diagnostic
Interview (Lord et al., 1994), and the Diagnostic and Statistical
Manual of Mental Disorders, 5th Edition (DSM-5) (American
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Psychiatric Association, 2013). Dysregulated emotional and
atypical physiological responses may underlie these features
(Woodard et al., 2012; Mazefsky et al., 2013; Levine et al., 2014;
Klusek et al., 2015; Lydon et al., 2016). Similarly, individuals
with ASD often demonstrate difficulties regulating their internal
emotional states (Mazefsky et al., 2013). As such, electrodermal
activity (EDA), a peripheral index of sympathetic nervous system
arousal (Boucsein, 2012), may be informative in ASD populations
(McCormick et al., 2014; Prince et al., 2017). For instance,
processing of social stimuli may differentiate ASD and TD
populations in terms of autonomic nervous system responsivity
(Louwerse et al., 2014).
Lab-Based Biosensors
Multiple brain systems are implicated in the formation and
maintenance of core deficits in ASD. Establishing peripheral,
non-intrusive methods such as EEG or eye tracking to interrogate
these deficits would allow for in vivo study and potentially
quantify ASD core deficits, as well as links to underlying ASD
neurobiology (Black et al., 2017). EEG may be well-suited for
detecting the alterations in brain connectivity found in ASD,
through the use of coherencemeasurements and other paradigms
(O’Reilly et al., 2017). Translational research suggests direct links
between ASD neurobiology and social deficits. For example,
EEG has been utilized in mouse models of Fragile X to link
to neurobiological substrates (Goswami et al., 2019). Significant
differences in EEG activity have been widely demonstrated in
studies to distinguish individuals with ASD from TD controls
(Gurau et al., 2017). Studies using eye tracking and event-related
potentials (ERPs) to examine emotional face processing suggest
that the neural correlates of gaze direction processing may be
delayed in young children with ASD (Grice et al., 2005; Wang
et al., 2013; Shou et al., 2017), and that individuals with ASD show
an atypical pattern of emotional face processing and a reduced
relationship between gaze behavior and neural processing of faces
(Wagner et al., 2013).
Visual information processing in TD individuals is reinforced
by additional speech information, demonstrating that TD
children’s ability to integrate multimodal input enables faster
encoding and recognition of faces (Bahrick, 1987; Carpenter
et al., 1998; Lydon et al., 2016). There is also evidence that face
detection is facilitated when combined with directed speech in
TD infants (Yirmiya et al., 1989). In contrast, children with ASD
are characterized by limited attention to faces combined with
under-responsivity to speech (Dawson et al., 2004; Wetherby
et al., 2004; Chawarska et al., 2012). Limited attention to faces
in individuals with ASD is particularly prominent when viewing
dynamic videos presented in complex naturalistic contexts (Speer
et al., 2007). It is possible that such limited attention to faces
is a direct result of increased salience of objects, which are of
high autism interest (HAI) (Senju et al., 2004; Sasson et al.,
2008, 2011). It is also expected that differences between ASD and
TD populations become apparent when dyadic cues consisting
of directed speech and eye contact are introduced (Chawarska
et al., 2016; Wang et al., 2018). Individuals with ASD assessed
by eye tracking show diminished attention to scenes where an
actress emulates bids for dyadic engagement, and spend less
time monitoring the speaker’s face in general and mouth in
particular. Instead, their attention is directed toward toys as well
as hand/action areas (Chawarska et al., 2012).
In contrast, when passively observing the interactions of
others, children with ASD exhibit diminished attention to
others’ functional play activities, in addition to limited attention
to faces (Shic et al., 2011). In combination, these studies
provide evidence that eye tracking can identify and measure
variables associated with limited social information processing
in ASD, limitations likely reflecting fundamental social deficits
in ASD and difficulties in subsequent social learning (Bushwick,
2001; Klin et al., 2003). Several studies have also suggested
that eye tracking can be used to monitor the effects of
pharmacological agents. For example, eye tracking studies have
shown that individuals with ASD look more at eyes subsequent
to administration of intranasal oxytocin (Andari et al., 2010;
Auyeung et al., 2015); another study found increased orienting
to biological motion subsequent to administration of a novel
V1a antagonist (Umbricht et al., 2017). Murias et al. used eye
tracking to demonstrate that improvements in social behavior
were correlated with increased attention to social stimuli (Murias
et al., 2018).
In the TD population, facial expressions activated via
automatic or intentional mimicry appear to influence
corresponding emotions, whereas the influence is impaired
in the ASD population (Tomasello et al., 2005). Consequently,
it is expected that individuals with ASD will show fewer facial
emotional reactions (i.e., less variance in emotion) compared
to TD individuals in response to videos designed to elicit
overt emotional states, such as humorous or funny videos. A
more neutral flatness of affect has been found in the activated
facial expressions of children with autism (Yirmiya et al.,
1989). It is also expected that facial expressions activated in
the ASD population will be diminished compared to those
of TD participants.
Finally, as suggested above, recent large scale trials (Bazelmans
et al., 2018), and systematic reviews (Klusek et al., 2015; Lydon
et al., 2016) of the literature on physiological reactivity to
sensory, social, and emotional stimuli indicate that differences in
cardiovascular arousal exist for many individuals with ASD.
Deep Phenotyping Tools in ASD
ASD interventions are frequently evaluated using caregiver-
reported measures administered during study visits. Two
common caregiver measurements of behavior change in ASD
are the Aberrant Behavior Checklist–Community (ABC) (Aman
et al., 2004; Aman and Singh, 2017) that measures general
behaviors, and the Social Responsiveness Scale 2
TM
(SRS-
2) that measures symptoms associated with social behaviors
(Constantino et al., 2003). While informative, these surveys are
retrospective, which can reduce rating accuracy. For example,
caregivers may report ASD symptoms as being worse in the
past compared to real-time reporting, even in the absence of an
intervention (Jones et al., 2015). Deficits in social communication
(SC) may be a risk factor for the development of mood
and anxiety disorders in ASD (De-la-Iglesia and Olivar, 2015;
Gotham et al., 2015). Some interventions directed at SC (6 of 10
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tested), led to improvements in depression and anxiety symptoms
in ASD (Rumney and MacMahon, 2017). Understanding
relationships between mental health and core ASD symptoms
could help identify specific interventions to improve quality of
life for individuals with ASD and their caregivers.
The Janssen Autism Knowledge Engine (JAKE R©) system
is an initiative to standardize physiological and psychological
instruments to reliably identify and measure core and associated
symptoms of ASD. A preliminary study was performed with
29 participants with ASD to test the feasibility of the JAKE
system and the learnings regarding logistics, data collection, data
quality, and analysis have been published (Ness et al., 2017).
The results obtained for the performance of the system allowed
for further refinement and validation of JAKE in this follow-up
study in a completely independent sample. As compared to the
initial study the system was complete and able to gather useable
data. System reliability, quality, user feedback, and representative
examples of results from the various components of JAKE are
described herein as well as participant demographics and safety.
Detailed methodology and results of the ABI, other components
of My JAKE, and the various sensors and tasks are published
elsewhere (Bangerter et al., 2017, In press; Manfredonia et al.,
2018; Manyakov et al., 2018; Jagannatha et al., In press) or are
in preparation.
MATERIALS AND METHODS
Study Design
JAKE is a dynamically updated clinical research system developed
to provide quantifiable and reproducible measures for use in
assessing treatment outcomes, potentially including detection
of change in ASD symptoms and ASD subgroup identification.
JAKE is a three-part investigational system consisting of: My
JAKE (a web and mobile application for use by caregivers and
clinicians to log symptoms, record treatments, track progress,
and gather comprehensive medical information); JAKE Sense
(research biosensors and tasks designed to detect and monitor
changes in experimental, proof-of-concept ASD biomarkers);
and JAKE Stream (a system designed to collect, time-
synchronize, and process data from both My JAKE [My JAKE
Data Pipeline] and JAKE Sense [JAKE Sense Data Pipeline]).
This prospective, observational, non-interventional study was
conducted from 06 July 2015 to 14 October 2016 at 9 study
sites in the US and was completely independent from a previous
study on the use of JAKE (Ness et al., 2017). The study
consisted of a 14-day screening phase followed by an 8-to-
10-week data-collection phase. Study visits were performed at
baseline, Week 4, and study endpoint (8–10 weeks). Evaluations
throughout the study encompassed several categories within the
FIGURE 1 | The JAKE system. ABI, Autism behavior inventory; HCP, health care professional.
Frontiers in Neuroscience | www.frontiersin.org 4 February 2019 | Volume 13 | Article 111
Ness et al. Autism Observational Study Using JAKE®
JAKE system (Figure 1). Though this was a non-interventional
study, participants received treatment as usual, and there was
some anticipated change in reported behaviors measured at
baseline and endpoint. Observed improvements or worsening
of behavior over the course of the study were used to assess
JAKE’s ability to detect change. This study was registered
with clinicaltrials.gov (NCT02668991).
Participants
The study enrolled males and females aged ≥6 years with
an ADOS-2-confirmed diagnosis of ASD. Participants were
permitted to receive behavioral and/or pharmacologic treatments
for ASD and comorbid disorders during the study, but this
was not required. Participants lived with a parent or primary
caregiver (or a guardian or support provider, referred to as
“caregiver” throughout this publication) or, if not, spent at least
3 h a day for at least 4 days each week or at least 3 weekends
a month with a parent or primary caregiver. Key exclusion
criteria were a measured composite score on the Kaufmann Brief
Intelligence Test-2 (KBIT-2) (Kaufman, 2004) of <60 during
screening (or other recent IQ evaluation), history of or current
significant medical illness, and documented psychological and/or
emotional problems.
The study also enrolled a TD cohort comprised of males
and females, aged ≥6 years, with a score in the normal range
on the Social Communication Questionnaire (SCQ) (Rutter
et al., 2003), no mental disorders as defined in the DSM-5, no
significant medical illness, or current psychotropic medication.
The TD cohort provided normative data for comparison
with ASD participants, completed standard instruments and
scales, a paper version of the ABI, and lab-based JAKE Sense
assessments, but did not use My JAKE. Planned study cohorts are
presented in Table 1.
Institutional Review Boards approved the study protocol and
its amendments. The study was conducted in accordance with
the ethical principles originating in the Declaration of Helsinki,
consistent with Good Clinical Practices and applicable regulatory
requirements. Participants, their caregivers (for participants <18
years old), or legally authorized representatives provided written
informed consent before participating in the study. The study is
registered at clinicaltrials.gov (NCT02668991).
Study Assessment Instruments and Scales
Throughout the study, data collected through My JAKE
and JAKE Sense were compared against psychometrically
standardized scales (completed outside the JAKE system) to
assess validity of the system as a tool for measuring clinical
outcomes in ASD (Table 2).
Deep Phenotyping Tools-My JAKE
My JAKE is a web and mobile application (iOS+/Android+)
consisting of various modules to help caregivers and healthcare
providers who support individuals with ASD to log symptoms,
demarcate events of interest, record treatments and medical
information, and track overall study progress. My JAKE was
developed, in part, to enhance the ability to understand the
phenotypic underpinnings of individuals with ASD and to
TABLE 1 | Planned study cohorts.
ASD Cohort TD Cohort
Approximately 150 individuals with ASD
aged ≥6 years
No requirements or restrictions regarding
concurrent therapies or treatments
Approximately 30 normally
developing individuals with ASD aged
≥6 years, with ∼5 individuals in each
subgroup of ages 6–9 years, 10–12
years, 13–17 years, and ≥18 years
A 14-day screening phase, and an
8–10-week data collection phase
extending from Day 0 (Baseline) to
endpoint was planned
Single visit and single session with
JAKE Task Battery and JAKE Sense
Optional: After the endpoint visit,
participants may continue to use My JAKE
and the Microsoft® HealthVault pHR to
contribute data to the study until the end
of the study
ASD, autism spectrum disorder; JAKE, Janssen Autism Knowledge Engine; pHR,
personal healthcare record.
address both a lack of appropriate measures and convenient
methods of use. The purpose of My JAKE is to provide a
robust and sensitive set of integrated outcome measures for ASD
clinical trials and other interventional studies in place of or in
addition to current measures that do not necessarily assess the
full range of ASD symptoms or were not designed to measure
change over time.
All data created and accessed by My JAKE were saved to a
caregiver’s Microsoft HealthVault account, a publicly-available
Class 1 electronic personal health record system. As the sole
storage mechanism for all My JAKE data, the use of HealthVault
permitted caregivers to own and control their dependent’s
study data, even after the study ended. Additionally, caregivers
controlled which people and applications could access their
HealthVault account at any time. The My JAKE application
server is hosted on Microsoft Azure.
My JAKE is accessible through most web browsers, as well as
mobile devices, and was used throughout the present study. The
My JAKE home page includes a “Journey” chart for visualizing
change of ASD “events” and selected symptoms, a study tasks
tracker (the “To-Do” list) to help caregivers monitor required
items, and a list of upcoming appointments (the Therapy
Tracker) (Figure 2). Other My JAKE components included:
Medical/Developmental History
A comprehensivemedical and developmental history filled out by
caregivers during the screening/on boarding phase of the study
and edited throughout.
The Autism Behavior Inventory (ABI)
An important element of My JAKE is the Autism Behavior
Inventory (ABI), a web-based caregiver-rated scale for assessing
ASD core diagnostic symptoms and associated behavior. The
development of the ABI component of My JAKE have been
previously published (Bangerter et al., 2017). The ABI consisted
of 73 items divided into five domains: two ASD core symptom
domains, SC, and restricted and repetitive behaviors (RRB); and
three symptom co-occurrence domains, mental health (MH),
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TABLE 2 | Study assessment instruments and scales.
Test Description
DIAGNOSTIC AND CLASSIFICATION INSTRUMENTS ADMINISTERED AT
SCREENINGa
Autism Diagnostic Observation
Schedule, 2nd edition (ADOS-2)
Used to accurately assess and diagnose
autism spectrum disorders across age,
developmental level, and language skills in ASD
participants
Kaufman Brief Intelligence Test,
Second Edition (KBIT-2)
A validated test used to obtain a quick estimate
of intelligence, administered at screening in
order both to help select participants capable
of performing the required tasks and for
analysis of data in ASD participants
The Mini International
Neuropsychiatric Interview 7.0
(MINI 7.0) or pediatric
component (MINI KID)
Used to rule out any major psychiatric
diagnosis in TD participants, and to identify any
psychiatric comorbidities in ASD participants
Social Communication
Questionnaire, current form
(SCQ)
A 40-item scale that evaluates social
functioning and communication skills over the
last 3 months, administered at screening. It
was administered only to the TD cohort, to help
rule out ASD
STANDARD INSTRUMENTS FOR MEASURING CHANGEb
Aberrant Behavior Checklist
(ABC)
A 58-item behavior rating scale, used to
measure behavior problems across 5
subscales: irritability, lethargy (social
withdrawal), stereotypy, hyperactivity, and
inappropriate speech (Aman et al., 2004; Aman
and Singh, 2017)
Zarit Burden Interview–Short
Version (ZBI)
A 22-item scale assessed the psychological
burden experienced by a caregiver, for both
patients with dementia and children and adults
with ASD (Zarit et al., 1980; Cadman et al.,
2012)
Social Responsiveness Scale 2
(SRS-2)
Distinguishes autism spectrum conditions from
other child psychiatric conditions by identifying
the presence and extent of autistic social
impairment (Constantino et al., 2003)
Child Adolescent Symptom
Inventory – Anxiety (CASI-Anx)
A 21-point anxiety scale used as a possible
outcome measure for autism (Sukhodolsky
et al., 2008; Hallett et al., 2013)
Repetitive Behavior
Scale—Revised (RBS-R)
(caregiver)
A 43-item report scale used to indicate
occurrence of repetitive behaviors and degree
to which a behavior is a problem (Bodfish et al.,
1999).
a Instruments used to establish the diagnosis of autism or help rule it out, to help classify
participants by intelligence quotient (IQ), or to rule out or rule in the presence of other
psychiatric disorders in participants.
bCaregiver-reported rating scales used to assess change over time in particular domains
of ASD symptoms and to validate components of the JAKE system. They were
administered only to ASD participants at baseline, midpoint and endpoint visits. Scales
were selected based on previous use in clinical trials for ASD, or recommendations in
reviews of scales for use in measuring change in ASD core and associated behavior
(Lecavalier et al., 2014; Anagnostou et al., 2015; Scahill et al., 2015) ASD, autism
spectrum disorder; TD, typically developing.
self-regulation (SR), and challenging behavior. The ABI yields a
score in each domain, plus a core score combining SC and RRB,
based on behaviors that occurred within the last 7 days. The ABI
can be downloaded in the USA from https://www.janssenmd.
com/ (in the tools/psychiatry section) and accessed outside the
USA via email request to autismbehaviorinventory@its.jnj.com.
Questions were asked on two 4-point scales and consisted of
either frequency and intensity ratings, frequency and context,
or quality and context. The full ABI was completed by
the primary caregiver at baseline, midpoint (Week 4), and
endpoint. A short (35-item) form of the ABI (ABI-S) was
completed by the investigator or delegate at baseline, Week 4,
and endpoint. The primary caregiver completed the ABI-S on
weeks when they were not required to complete the full ABI
(Weeks 2, 3, 5, 6, and 7).
The Daily Tracker
The Daily Tracker consisted of several questions answered by
caregivers of ASD participants. In this study, all caregivers were
asked in the morning “How was (participant name)’s sleep last
night?” and in the evening “How was (participant name)’s day?”
Caregivers could also choose up to three additional behaviors
to track, but only the two standard questions were analyzed.
Questions could be answered by dragging a card along an 8-point
scale ranging from “troubling” to “encouraging” either on theMy
JAKE mobile application or in a web browser. Responses to these
questions were tracked and displayed over a 2-week period on the
web site home page to provide feedback to caregivers and increase
engagement in the study.
Mood Report
The affective circumplex model of affect reporting has a long
and widespread history in measuring affective/emotional states,
including those with ASD (Kring et al., 2003; Tseng et al.,
2014). A digital version of the classical affective circumplex
was created for the My JAKE mobile application for this
study. The x-axis represents arousal, termed “activity,” and
the y-axis represents valence, termed “mood.” The model was
divided into “Quadrants” of activity and mood relationships.
Caregivers moved the icon to a location on the screen that
represented their child’s perceived mood at the moment; they
were asked to do this twice a day but could do so as many
times as desired.
Event Tracker and Journal
Caregivers tracked all items of interest, including sleep and
diet, on a daily basis. They were also able to provide free text
entries ad-hoc to track both positive and negative events as
they occurred.
Therapy Tracker
This module allowed tracking of participants’ medical treatments
or therapies, using a calendar-like interface. Caregivers had the
option to export their created appointments to the calendaring
system of their choice.
Biosensor Data-JAKE Sense
JAKE Sense is based on the use of experimental biosensors to
assess physiological characteristics and behavior related to core
and associated symptoms of ASD. The biometric devices can be
divided into two categories: lab-based biosensors, which measure
biometric information in a laboratory setting (usually paired
with challenge tasks or stimuli presented on a computer screen)
and continuous biosensors, designed for daily wearable use to
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FIGURE 2 | Sample My JAKE home page. ABA, Applied behavior analysis.
collect real-world biometric information about the participant.
The selected biosensors (and their output) were used strictly for
exploratory research purposes and were not used to diagnose,
treat, or prevent any disease or disorder. All devices were used
in compliance with their documented intended use.
Biosensors
Continuous Biosensors
The “daytime biosensor” (Empatica E4TM Wristband) is a
commercially-available wireless wristband biosensor that records
EDA, skin surface temperature, blood volume pulse and inter-
beat interval (producing an approximation of heart rate and heart
rate variability), and 3-axis acceleration. The E4 has been used in
previously published research (Goodwin et al., 2018) involving
youth with ASD in the current study’s participant age range (≥6
years of age) and did not require alterations to the band in either
study to acquire quality signals. Both the EDA (Poh et al., 2010;
Sano et al., 2014) and photoplethysmography sensors (McCarthy
et al., 2016) in the E4 have been independently validated. It was
worn during waking hours, at minimum for the afternoon until
bedtime on weekdays, at periodic lab visits, and the entire day
on weekends.
A “nighttime biosensor,” the commercially-available
Ambulatory Monitoring, Inc. (AMI) Motionlogger R© Actigraph
was worn at bed-time for the entire night’s sleep. Each
night’s sleep start time, number of awakenings during sleep,
time duration of sleep, and sleep efficiency were derived
from measurements recorded by the sensor (Acebo et al.,
1999; Wiggs and Stores, 2004; Souders et al., 2009; Gringras
et al., 2012; Meltzer et al., 2012), and have been validated in
children with ASD.
Lab-Based Biosensors
These biosensors were used at a study visit while participants
were exposed to specific visual or auditory stimuli or asked to
perform a task (Table 3). Tasks and stimuli for use with lab-based
biosensors comprised a battery of ∼40min for use at laboratory
sites. Participants were asked to wear or use all the lab-based
biosensors (in addition to the daytime continuous biosensor
described above) during presentation of all tasks and stimuli.
Tasks and stimuli were presented on a computer monitor using
the iMotions R© Biometric Research Platform (formerly called
Attention Tool). The continuous and lab-based sensors were
found to be tolerable (Ness et al., 2017).
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TABLE 3 | Tasks or stimuli (the JAKE Task Battery) for use with lab-based biosensors.
Task/Stimulus Description Biosensor
Eye
tracking
EEG FACET ECG EDA
Resting state-eyes open
(Murias et al., 2007)
Video of sand falling through an hourglass for 1min x * x x
Resting state-eyes closed
(Murias et al., 2007)
Participant asked to close their eyes for 45 s * x x
Event related potentials
(Grice et al., 2005)
Static facial stimuli with averted or direct gaze x * x x
Social orienting task
(Chawarska et al., 2012;
Plesa-Skwerer et al., 2016)
Video of male or female actor presented in random order;
actor engages participant in direct speech (dyadic bid) and
joint attention, toward or away from a moving toy
* x x
Social vs. non-social videos
(Pitcher et al., 2011)
Dynamic videos of children’s faces (social) or toys (non-social) x * x x
Visual exploration task
(Sasson et al., 2008, 2011)
Free viewing of Arrays of 24 images (including social images,
HAI and LAI objects)
* x x
Biological motion (Umbricht
et al., 2017)
2 side by side videos, in random left-right order. Each video
contains dynamic point-light displays. One video is derived
from human actor’s performance; the other video is a
computer-generated animation of moving dots
* x x x
NimStim emotional faces
(Wagner et al., 2013)
Static images of happy, angry, fear, and neutral faces x * x x
Activity monitoring (Shic
et al., 2011, 2014; Umbricht
et al., 2017)
Video recording of multiple human actors performing a social
activity, with visually salient distracters in the background;
actors focus on each other or on the activity only in 2
conditions
* x x
Funny videos Funny videos, or videos designed to elicit an emotional
response of surprise or joy
* x x
Expression of emotional
faces
Participants asked to make faces to reflect basic emotions:
Happy, Sad, Surprise, Scared, Angry, Yucky (disgust).
* x x
Auditory stimuli 3 sets of auditory stimuli (toilet flush, a ticking clock, or an
880 hz tone) presented for 3 s duration each, with ISI of
8–12 s each. Screen displayed bubbles screen saver and a
progress bar indicating time until the presentation was
complete.
x * *
*primary hypotheses.
x, additional hypotheses.
ECG, electrocardiogram; EDA, electrodermal activity; EEG, electroencephalogram; FACET, FACial Expression; HAI, high autism interest; ISI, interstimulus interval; LAI,low autism interest.
Eye tracking data were collected using the Tobii X2-30 and
synchronized with stimuli and facial affect data through the
iMotions R© eye tracking module.
EEG data were collected using the Brain Vision actiCHamp
32 and its proprietary software (BrainVision Recorder). A
total of 20 electrodes were placed in accordance with the
standard 10–20 electrode system. The use of a photodiode
attached to the lower-right corner of the computer monitor
allowed the software to precisely timestamp stimuli
slide changes.
Electrocardiogram (ECG) data were collected using the
CamNtech Actiwave Cardio Single-Channel ECG and used to
assess heart rate and heart rate variability.
Facial affect detection was evaluated using the iMotions R©
FACial Expression Analysis (FACET) module and a high
definition web camera.
An assembled JAKE Sense setup is shown in Figure 3.
JAKE Stream
JAKE Stream was designed to collect and process data from
both My JAKE and JAKE Sense. JAKE Stream is divided into
two physically distinct subcomponent sets of Microsoft.NET
command line utilities hosted on Janssen servers: “My JAKEData
Pipeline” and “JAKE Sense Data Pipeline.”
The My JAKE Data Pipeline was designed to capture and
process a daily archive of My JAKE data stored in a caregiver’s
and/or participant’s Microsoft HealthVault account (described
earlier). After the My JAKE Data Pipeline processed daily
capture, data were directed to an internal Janssen server for
traceability archiving/auditing and then ultimately to the Janssen
data management team (via secure file transfer server) for
incorporation into final study results. A site manager dashboard
was used to view a read-only copy of My JAKE data stored on the
internal Janssen server for monitoring participant, caregiver, and
clinical site usage of web and mobile applications.
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FIGURE 3 | Assembled JAKE Sense workbench cart. ECG, electrocardiogram; EEG, electroencephalogram.
Similarly, the JAKE Sense Data Pipeline was designed to
process and extract biometric features from data packages
provided by JAKE Sense. Examples of the types of features
that were extracted are shown in Table 4. After packages were
archived to ensure traceability of derived analyses, a collection
of MATLAB utilities scanned the packages to produce a series of
extracted features (as flat.CSV-formatted files). Finally, the files
were stored in a secured datastore server (“JAKE Sense Data
Pipeline Features Archive”) for exploratory, proof-of-concept
data mining; data are not used for clinical trial endpoints or for
clinical decision-making.
Data Quality Control
All features extracted from data collected by JAKE were assessed
and labeled according to their fidelity and quality (Webb et al.,
2015), with analyses performed only on features reaching the
following criteria:
As an automatic first step, EEG and eye tracking features were
estimated on three levels, with data designated as “excellent,”
“excellent+good,” and “any” quality. These three levels were
defined as follows:
For eye tracking: “excellent” corresponds to the related value
of calibration as defined by the iMotions R© Biometric Research
Platform software; “excellent+good” combines recordings with
“excellent” and “good” calibration as defined by the software;
and “any” corresponds to “excellent,” “good,” or “bad” calibration
results as defined by the software.
For EEG: “excellent” corresponds to impedance below 25
kOhm; “excellent+good” corresponds to impedance below 50
kOhm; and “any” corresponds to any value of impedance.
Additionally, we considered information from the eye tracker
relating to times when participants were attending to the screen
during EEG processing, allowing EEG segments corresponding
to an absence of attention to be excluded from feature estimation.
The use of “recalibration” videos embedded in the stimuli battery
also allowed eye tracker calibration consistency to be checked
throughout experiments. EEG data were further evaluated for
eye-blinking artifacts and consequences of bridging electrodes.
Corresponding EEG segments per channel (or data from a whole
channel) were labeled accordingly.
Feature estimation algorithms incorporated information from
these labels, wherein features were only estimated when no
artifacts were identified. Artifact identification was performed
by assessing mean, SD, maximum, minimum, median, mode,
skewness, and kurtosis of EEG data values by applying
sliding windows and comparing obtained distributions between
channels with preset parameters in order to identify outliers.
Since EEG follows 1/f distribution (pink noise) in the frequency
domain, model slope, and model intercept for power spectrum
density were estimated in sliding window segments and also
checked for outliers via comparison of distributions between
channels and with preset parameters. As a result of this
artifact rejection step, diagnostic plots were created and visually
inspected during subsequent manual quality checks.
After all features were automatically extracted, an expert
manually checked the diagnostic plots produced during the
automatic quality check including 1/f pink noise shape for
spectra, presence of components for ERP, signal-to-noise ratio,
detection of N peaks for ECG, and valid time for eye tracking
to make additional quality determinations. This assessment
resulted in modification of files with questionable data quality
information and sometimes resulted in re-estimation of all
features if necessary.
EDA data were manually and automatically inspected
according to established guidelines (Dawson et al., 2007;
Boucsein et al., 2012; Kleckner et al., 2018). This enabled
identification of parts of recordings or whole recordings where
data were missing (e.g., straight line at zero level), had poor signal
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TABLE 4 | Example features.
Eye-tracking EEG ECG EDA Actigraphy FACET
Tobii X2-30 Brain Vision ActiCHamp 32 CamNtech Actiwave Cardio
Single-Channel ECG
Empatica E4TM AMI Motionlogger®
Actigraph
iMotions® FACial
Expression
General features
• Fixations and saccades
(using velocity based
binocular algorithms)
• % valid time on screen
• % on ROIs (also
normalized to % valid
time)
• Pupil size
Specific features
• Biological Motion
preference (%), first
saccade orienting (%)
saccade latency, fixation
orienting (%), fixation
latency
• VET exploration,
preservation, detail
orientation, RQA features
Induced EEG activity (estimated
for each electrode and different
brain region)
• Power spectra at different
bands (delta, theta, alpha,
beta, gamma)
• Normalized power spectra at
different bands
• Brain asymmetry index for
different bands
• Coherence between at
different bands
ERP
• Components’ amplitudes with
peak- and area-based
methods
• Components’ latencies with
peak- and area-based
methods
• HR
• SDNN
• SDSD
• rMSSD
• NN50
• pNN50
• ApEn
• SpEn
• LF HRV
• Normalized LF HRV
• HF HRV
• Normalized HF HRV
• LF/HF HRV
Tonic activity
• SCL
Phasic activity:
• SCRR
• Sleep duration
• Sleep start
• Sleep end
• # awakenings
• Sleep efficiency
For each emotion (joy, anger,
surprise, fear, contempt,
disgust, sadness, confusion,
frustration) and action unit
defined according to FACS
• Average evidence
• Variance of evidence
• Area under evidence
curve
ApEn, approximate entropy; ECG, electrocardiography; EEG, electroencephalograpy; EDA, electrodermal activity; ERP, event-related potentials; FACET, iMotions® FACial Expression
analysis; FACS, Facial Action Coding System; HF, high frequency; HR, heart rate; HRV, heart rate variability; LF, low frequency; NN50, number of pairs of successive NNs that differ by
more than 50ms; pNN50, proportion of NN50 divided by total number of NNs); rMSSD, root mean square of successive differences; ROI, Region of interest (such as eye region, mouth
region, face region, and so on); RQA, recurrence quantification analysis; SCL, skin conductance level; SCRR, skin conductance response rate; SDNN, standard deviation of normal to
normal R-R intervals; SDSD, standard deviation of successive differences; SpEn, sample entropy; VET, visual exploration task.
quality, or were otherwise noisy. These values were subsequently
excluded from analyses.
Exit Interview
Caregivers were asked to provide final feedback on their
experience with JAKE in an exit interview and a 36-question
on-line survey. Examples of questions were “which JAKE
components would you like to use outside of a clinical trial” and
“how easy were the following tasks to complete.”
Genomic Assessment
A genomic cheek swab sample was collected from ASD
participants who consented separately to this component of the
study. Participation in genomic research was optional.
Safety Evaluations
All reported study events (intercurrent illnesses, changes in
signs/symptoms, early discontinuations, device-related events,
etc.) with onset during study participation were included in
evaluations. For each event, percentages of participants who
experienced at least one occurrence were summarized.
Data Quality Assurance
Steps taken to ensure accuracy and reliability of clinical study
data included selection of qualified investigators and appropriate
study sites, review of protocol procedures with investigators and
associated study-site personnel prior to study start, and periodic
monitoring visits by the sponsor or their delegate.
Data Analyses
All analyses performed for this study were exploratory. Pre-
specified hypotheses relating to My JAKE and JAKE Sense were
developed prior to conducting analyses. The overall Type I
error rate for testing each hypothesis when two variables were
assessed for correlation or the difference between ASD and TD
participants involved a 2-sided or 1-sided significance level of
0.05. No adjustments for collinearity, multiplicity, or experiment-
wise error were made as results were intended for hypothesis
generation, not confirmation. Where presented, all confidence
intervals are 2-sided at 95%, which correspond to a 2-sided
significance level of 0.05 and a 1-sided significance level of 0.025.
Descriptive statistics were provided for all study evaluations at
baseline, Week 4, and study endpoint.
RESULTS
Study Population
A total of 144 participants with a diagnosis of ASD were
enrolled. Of these, 136 (94.4%) participants completed the study
and 8 (5.6%) discontinued. The most common reason for
discontinuation was self-withdrawal from the study (6 [4.2%]).
The reasons for self-withdrawal were not reported. A total of
41 TD participants were enrolled and all (100%) completed the
single visit of the study.
The ASD study population was primarily male (77.8%),
consistent with higher male:female ratios for ASD (Loomes et al.,
2017). The mean (SD) age of ASD participants was 14.6 (7.83)
years compared with a mean (SD) age of 16.3 (13.18) years
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for TD participants. Mean (SD) ADOS total score of the ASD
participants was 7.6 (1.7), their IQ was 99.2 (19.6), and all were
verbal (Table 5).
Data Capture and Quality
My JAKE
Overall, My JAKE was used an average of four times a day by
each primary caregiver throughout the course of the study for
over 34,000 distinct interactions.
As designed, My JAKE used at study sites captured the ABI
with no missing items. On rare occasions, a few items were
missing when a paper alternative was used due to internet failure
at the sites.
The average (SD) number of reports for all participants for
mood and overall type of day were 61.2 (35.9) and 29.8 (17.3),
respectively, per caregiver over the course of the study.
JAKE Sense
Automated and manual curation of JAKE Sense data was
used to assess amount and quality of data obtained from the
various sensors and to exclude poor quality data from analyses.
Table 6 shows the percentage of total features captured and
the percentage of captured features classified as suitable for
analysis (good) by sensor and experiment for ASD participants
at the baseline visit using the current version of the data quality
algorithms and feature extractors.
The proportion of good features obtained (93.2–100%) was
generally high for most of the experiments, although a lower
overall proportion (45.6–83.8%) was seen in all EEG variables
(biological motion, ERP, resting state, social vs. non-social videos,
and NimStim) and EDA experiments (80.1–83.8%). Additionally,
TABLE 5 | Participant characteristics.
Characteristic ASD
N = 144
TD
N = 41
GENDER, n (%)
Male 112 (77.8) 27 (65.9)
Female 32 (22.2) 14 (34.1)
AGE
Mean (SD) 14.6 (7.83) 16.3
(13.18)
Median (Range) 12.5 (6–54) 11.0 (6–63)
RACE, n (%)
White 118 (81.9) 34 (82.9)
Black or African American 6 (4.2) 2 (4.9)
Asian 4 (2.8) 0
Multiple 10 (6.9) 3 (7.3)
Other 4 (2.8) 0
Missing/unknown 2 (1.4) 2 (4.9)
ADOS CSS Total Score, mean (SD) 7.6 (1.7) –
KBIT-2 IQ Composite Score, mean (SD) 99.2 (19.6) –
ADOS, autism diagnostic observation schedule; ASD, autism spectrum disorder; CSS,
calibrated severity score; KBIT-2 IQ, Kaufman brief intelligence test, second edition; IQ,
intelligence quotient; SD, standard deviation; TD, typical developing.
many of the EEG and EDA experiments had a relatively lower
percentage of captured features than seen in the ECG, eye
tracking, and facial affect experiments.
Autism Behavior Inventory (ABI)
While full results of the ABI have been submitted as a separate
manuscript, in short, the ABI performed well, with excellent test-
retest reliability and strong correlations between domains and
scales prospectively hypothesized to measure similar constructs
(the core ABI Pearson correlation with the SRS-2 (0.81), ABI
restrictive behaviors with RBS-R (0.77), ABI mental health with
CASI-anx (0.78), ABI self-regulation with ABC hyperactivity
(0.88), and ABI challenging behavior with ABC irritability
(0.81). Conversely, as expected, lower correlations were observed
where different symptom clusters were assessed, such as between
the ABI challenging behaviors domain and the SRS-2 social
communication and interaction score (0.32) (Table 7).
Test-retest reliability of each domain score 3 to 5 days after
baseline was excellent, with Intraclass correlation coefficient
values ranging from 0.85 to 0.95. Means did not change
significantly between test and retest (Table 8).
My JAKE
Representative examples of results from My JAKE are shown in
Figure 4. The mood report positive valence percentage showed a
negative correlation with the ABI challenging behavior subscale
at endpoint visit (r = −0.30, p = 0.004) indicating that more
positively perceived mood correlated with a more favorable
TABLE 6 | Quantity and quality of data obtained from JAKE Sense biosensors
(using current data quality algorithms and feature extractors).
Sensor Experiment Features
Captured (%)
Good
Features (%)
ECG Eyes closed 97 98
ECG Eyes open 94.8 97.9
EDA Ticking clock 75.4 81.3
EDA Toilet flush 75.4 83.8
EDA Tone 76.3 80.1
EEG BioMotion 80.5 60.7
EEG ERP experiment 81.3 75.7
EEG Social vs. non-social video 82.3 63.6
EEG NimStim 80.3 45.6
EEG Resting state 81.4 49.2
EYE Activity monitoring 83.1 99.9
EYE Biological motion 85.9 100
EYE Social orienting task video 70.3 99.8
EYE ERP experiment 86.7 100
EYE Social vs. non-social video 91.1 100
EYE NimStim 81.5 100
EYE VET 89.9 99.9
FACET Facial expression production 95.3 93.2
FACET Funny videos 95.5 98.3
ECG, electrocardiogram; EDA, electrodermal activity; EEG, electroencephalogram; ERP,
event-related potential; FACET, FACial Expression; VET, visual exploratory task.
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TABLE 7 | Pearson correlations between ABI scales and subscales and related patient reported outcome measures.
Analysis time point related PRO measure Core ASD
symptoms
Social
communication
Restrictive
repetitive behaviors
Mental
health
Self-
regulation
Challenging
behavior
ABI SCALE
Baseline (N = 139)
SRS-2 (Caregiver)
Total score 0.81 0.65 0.74 0.50 0.47 0.35
Social communication and interaction 0.80 0.68 0.69 0.48 0.43 0.32
Restricted interests/repetitive behavior 0.71 0.46 0.76 0.49 0.52 0.41
CASI-Anx
Anxiety scale score 0.54 0.34 0.58 0.78 0.38 0.25
RBS-R
Overall score 0.68 0.40 0.77 0.45 0.52 0.42
ABC-Community
Irritability/agitation 0.50 0.26 0.61 0.56 0.68 0.81
Lethargy/social withdrawal 0.70 0.69 0.52 0.35 0.17 0.19
Stereotypic behavior 0.60 0.40 0.64 0.36 0.53 0.42
Hyperactivity/non-compliance 0.44 0.23 0.54 0.30 0.88 0.54
Inappropriate speech 0.59 0.33 0.69 0.40 0.65 0.48
ABC, Aberrant Behavior Checklist; ABI, autism behavior inventory; ASD, autism spectrum disorder; CASI-Anx, Child Adolescent Symptom Inventory – Anxiety; PRO, Patient Reported
Outcome; RBS-R, Repetitive Behavior Scale – Revised; SRS-2, Social Responsiveness Scale 2; ZBI, Zarit Burden Interview.
TABLE 8 | Test-retest correlations for all ABI subscales based on caregiver responses to ABI.
Core ASD
n = 88
Social communication
n = 87
Restrictive repetitive
behaviors n = 88
Mental health
n = 88
Self-regulation
n = 88
Challenging
behavior n = 88
ICC estimate 0.91 0.91 0.88 0.85 0.92 0.95
p-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
95% CI (0.88, 0.94) (0.87, 0.94) (0.83, 0.92) (0.78, 0.90) (0.88, 0.95) (0.92, 0.97)
p-value for difference from a one-sample t-test. Pearson correlation based on test and retest values. ICC was 2, 1 variant. ICC, intraclass correlation coefficient.
challenging behavior score (Figure 4A). Figure 4B illustrates that
average perceived type of day negatively correlated with ABI Core
score at baseline (r = −0.42, p <0.001), indicating that a better
day correlated with a better ABI Core score.
JAKE Sense
Examples of results generated by the EEG (A), FACET (B),
and eye tracking components (C) of JAKE Sense are shown in
Figure 5. The N170 amplitude (a measure of face processing
in the ERP direct and averted gaze paradigm) displayed a
difference between TD and ASD participants (Figure 5A).
TD participants showed greater evidence of “happy” facial
expression production in response to being asked to produce a
happy face (Figure 5B). Also, the more time ASD participants
spent looking at the eye region of images of faces in the
direct and averted gaze paradigm, the better they scored on
the ABI social communications domain (Figure 5C). Detailed
presentations of results on FACET and eye-tracking are available
elsewhere (Manfredonia et al., 2018; Manyakov et al., 2018) and
manuscripts of additional results from these and other sensors
are in preparation.
Caregiver Feedback
Most caregivers provided positive feedback on overall ease of
use and utility using My JAKE for reporting and monitoring
behaviors (Figure 6). Caregivers viewed the website as “easy”
or “very easy” to use (69%, 74/108). Mobile application use by
caregivers was rated as “easy” or “very easy” to use (74%, 80/108).
Fifty-five percent (59/107) of caregivers were “likely” or “very
likely” to use My JAKE outside of a clinical trial. Overall reaction
to My JAKE was “positive” or “very positive” from 79% (85/108)
of caregivers. For the majority of caregivers, their impression of
use of the AMI Motionlogger actigraph by the participant was
very comfortable (37%, 22/103) or comfortable (55%, 57/103).
Participant’s use of the Empatica E4 was reported as comfortable
(34%, 23/68), neutral (26.5%, 18/68), or very comfortable
(24%, 16/68).
Safety
No significant device-related study events were reported.
Approximately 40% of participants (57/144) with ASD had at
least 1 event during the study (Table 9). The most frequently
reported study events (≥1.0% of participants) were upper
respiratory tract infection 6.9% (10/144), headache 4.2% (6/144),
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FIGURE 4 | Mood report (A) and daily tracker (B) correlations with ASD symptoms. ABI, Autism Behavior Inventory; ASD, autism spectrum disorder; TD, typically
developing.
FIGURE 5 | Difference in N170 amplitudes between ERP responses to direct and averted gaze stimuli at electrode T7 in TD and ASD participants (p = 0.053)
(A), Difference in production of “Happy” facial expressions between TD and ASD participants (B), and Correlation between percentage of time spent by a participant
looking at eye region (across both averted and direct gaze stimuli) corrected for total valid time (time on screen) and ABI social communication scales (C). ABI, Autism
Behavior Inventory; ASD, autism spectrum disorder; ERP, event-related potentials; TD, typically developing.
and nasopharyngitis 3.5% (5/144). No events were reported with
the TD participants.
Three of 144 ASD participants (2.1%) reported study events
which were moderate or severe in intensity and designated as
serious by the investigator. One participant reported an event
of abdominal pain on study Day 40, which was of moderate
intensity and resolved after 6 days. One participant reported
an event of suicidal ideation on study Day 1, which was of
severe intensity and resulted in psychiatric hospitalization. The
participant was discontinued from the study due to this event.
One participant reported two episodes of severe psychiatric
decompensation. The first event occurred on study Day 23 and
resolved after 8 days. The other event occurred on study Day 39
and resolved after 9 days.
DISCUSSION
The complexity and heterogeneity of ASD has contributed to
difficulties finding effective and scalable therapies to treat core
symptoms. Emerging tools and technologies have the potential
to improve our ability to measure change more sensitively and
to identify subgroups of individuals potentially responsive to
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FIGURE 6 | Results of exit survey completed by caregivers of children with ASD. ASD, autism spectrum disorder.
novel therapies. In this study, we report on the practicality
of combining and scaling multiple methodologies including
biosensors and clinician and caregiver reporting to measure
outcomes in a multisite study of children, adolescents, and adults
with ASD. Recently, results from specific features of My JAKE
and JAKE sense have been reported (Bangerter et al., 2017, In
press; Manfredonia et al., 2018;Manyakov et al., 2018; Jagannatha
et al., In press; Sargsyan et al., In press).
Data Capture and Quality
An important feasibility metric is the amount and quality of
data collected. Both JAKE Sense and My JAKE demonstrated
high levels of performance as indicated by user feedback and the
capture and quality metrics presented.
Capturing quality data in clinical trials for ASD is difficult
due to cost and complexity, particularly when biosensors are
included as outcome measures. Sample sizes are therefore often
small, which prevents development of approaches for within-
group stratification (Loth et al., 2017; Howes et al., 2018). There is
a need for big data rich in features, gathered across a large sample,
and at multiple levels across the same individuals (Lombardo
et al., 2018). This study represents a successful attempt to gather
this type of data in a large number of individuals with ASD
across a range of levels of development and ages. Of particular
importance is the number of sites involved (9) and the range of
expertise of the sites in the use of biosensors (some sites had never
used an EEG or eye tracker prior to this program), as well as the
use of portable devices scalable to larger numbers of sites in a
manner not prohibited by size or cost.
JAKE Sense
The collection of hardware and software known as JAKE Sense
enables collection of a wealth of synchronized data across
multiple sensor modalities and stimulus paradigms. The ECG,
eye tracker, and FACET sensors had minimal poor or missing
data while data quality was more problematic for EDA and EEG.
Because of technical difficulties encountered in gathering EDA
data from the home (for example connectivity issues) and the
relatively lower quality of this data compared to other metrics
when it was obtained at the sites, EDA has been removed
from regular use in future studies within the JAKE system.
Rather, participants will be given a single actigraphy device for
continuous wear (day+sleep). EDA devices using adhesive wet
electrodes may be another option for clinical studies.
The Brain Vision EEG collected reliable and valid data, but
the proportion of test sets with acceptable data still needs
improvement. Based on direct communication with study sites
and analysis of session flow, a number of improvements are
being implemented: (a) EEG will be integrated directly into the
iMotions R© Biometric Research Platform so as not to require
separate recording software running simultaneously; (b) the
process to ensure the photodiode is connected and functioning
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TABLE 9 | Incidence of study events in ≥1.0% of participants.
ASD (N = 144)
n (%)
TD (N = 41)
n (%)
Participants with at least one study event 57 (39.6) 0
Upper respiratory tract infection 10 (6.9) 0
Nasopharyngitis 5 (3.5) 0
Otitis media 3 (2.1) 0
Sinusitis 3 (2.1) 0
Gastroenteritis 2 (1.4) 0
Influenza 2 (1.4) 0
Respiratory tract infection viral 2 (1.4) 0
Urinary tract infection 2 (1.4) 0
Cough 2 (1.4) 0
Nasal congestion 2 (1.4) 0
Rhinorrhea 2 (1.4) 0
Headache 6 (4.2) 0
Migraine 2 (1.4) 0
Vomiting 3 (2.1) 0
Abdominal pain 2 (1.4) 0
Aggression 3 (2.1) 0
Seasonal allergy 4 (2.8) 0
Rash 2 (1.4) 0
Pyrexia 2 (1.4) 0
ASD, autism spectrum disorder; TD, typically developing.
will be improved; (c) increased training in EEG setup and
cap/electrode/impedance procedures, and (d) components of the
EEG will be made more water-resistant to prevent damage.
Compared to our previous study where useable data was only
gathered from ECG and FACET (Ness et al., 2017), the version
of JAKE Sense used in this study, as described in Methods,
represents a significant improvement in data collection. Even
for EEG data which is often reported as more difficult to obtain
(Gurau et al., 2017), and which had relatively lower success rates
then our other sensors, substantial amounts of good quality data
was obtained. Method changes that were implemented in this
study such as better training of site personnel and change of EEG
device contributed to the improved quality of data.
Based on feedback from sites and analysis of results,
shortening the stimuli battery would also improve tolerability
and attention of participants. Considering the length of various
stimuli together with the proportion of high-quality data they
provide, it is likely that ERP eye gaze, NimStim, and social
vs. non-social video stimuli will be removed from the battery.
Other tasks, for example biological motion, will be reduced in
duration. “Funny videos” will be retained and refined, including
the inclusion of sound, as these were reported to maintain
interest of participants. The auditory task will be revised and an
additional physical challenge (orthostasis) task will be added to
specifically probe for changes in ECG measures. The result will
be a task battery with two parts, each lasting <15min.
A novel ERP task that compares EEG response to social and
non-social still images of HAI will also be added (Benning et al.,
2016). ERP tasks are lengthy in nature, and the EEG set up is
more arduous than other biosensors, but these assessments might
indicate biological differences in ASD vs. TD individuals. Similar
stimuli designed to elicit differences in brain-based responses are
also a key component of other leading biomarker studies in ASD.
For example, EU-AIMS includes EEG resting state and social and
non-social videos in their battery of tasks (Loth et al., 2017). The
ABC-CT, a longitudinal study of school-age children with ASD
and typical development, is making similar efforts by evaluating
a wide range of EEG and eye tracking biomarkers and their
associations with caregiver-report and clinician-administered
assessments of social communication skills (McPartland, 2018).
A key distinction is the restriction of these studies to expert,
academic sites. Furthermore, the ABC-CT focuses specifically on
social communication skills as the primary endpoint, whereas
JAKE includes a wider range of clinical endpoints, such as RRB,
challenging behaviors, and mood.
My JAKE
My JAKE was effective in engaging caregivers during the
study and successfully captured data encompassing a broad
range of demographic, medical, developmental, educational,
and psychological aspects of ASD. The website and mobile
applications were extensively used by caregivers throughout the
study. Caregivers were prompted by My JAKE to complete the
ABI and were able to use the web application to enter data on a
full range of ASD symptoms.
User Experience
Another important feasibility metric is user experience. Feedback
from caregivers, both systematic (through the Exit Survey)
and informal (through communication with study centers) was
positive. The majority of caregivers found the system easy
to use, helpful, and of interest to use again, even outside of
a study. Though no major changes in My JAKE other than
those discussed above are anticipated prior to deployment in
interventional studies in autism, further refinements are planned,
including improving charting features, enhancing the mood
report, and modifying requirements for frequency of completing
various components. These refinements are intended to increase
acceptability to and use by caregivers.
To improve caregiver experience completing the ABI, analyses
of data obtained in this study will focus on further decreasing
user burden and simplifying scoring. Possible options under
consideration include changing the number of anchors and
altering the item filtering logic.
It is also anticipated that a decrease in duration of the
JAKE Sense task battery will improve participant experience and
tolerability. Consolidation of wearable home-based sensors to a
single wrist-worn actigraph, rather than a different device for
night time (actigraph) and day time (actigraph+ EDA), may also
improve compliance.
Clinical Significance
Perhaps most importantly, clinical relevance of data acquired
must be examined. We have reported on biosensor data
analysis from facial expressions (Manfredonia et al., 2018)
and eye tracking (Manyakov et al., 2018) and found both
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have the potential to aid with diagnosis and evaluation
of clinical symptoms of ASD. Data mining methods of
biosensor data were investigated as an approach to enable
objective discrimination between ASD and TD individuals to
potentially subgroup ASD participants based on phenotypic
data gathered by JAKE (Jagannatha et al., In press). In
addition, predictive modeling using biosensor-based feature
selection was explored to examine how changes in these features
correlated with clinical assessments (Sargsyan et al., In press).
We are preparing additional results obtained by the various
components of JAKE Sense, focusing on differences between
TD and ASD participants’ correlations between sensors and
ASD severity and symptoms as measured by the ABI, and on
changes over time. Genomic analysis will attempt to correlate
polymorphisms in distinct genetic pathways with differences in
autism phenotype.
In this study, we demonstrated the domains of the ABI
were highly correlated with standard scales measuring the same
constructs while comprising far fewer items than the combined
battery of these scales. A complete presentation of results of the
ABI from this study has been submitted for publication.
Similarly, the utility of My JAKE for capturing real-time daily
reports was demonstrated, and further exploration of system
elements and relationships of reports to other measures are
underway. Clinical endpoints measured by components of My
JAKE, such as the Daily Tracker and Mood Report, showed
that even simple methods may be useful for measuring the
effectiveness of interventional therapy.
Limitations
Limitations of this study include a caregiver burden that was
sometimes considerable, and the task battery being stressful for
some participants. Technical failures with various sensors of
JAKE Sense such as EDA and EEG also limited data capture.
Improved algorithms for use in analyses of various sensor data
and in data cleaning will also be explored.
A recent study (Anusha et al., 2018) suggests that dry
electrodes on dry skin should be worn for at least 27min
before a sufficient moisture barrier is built up to produce stable
EDA values. Although sites were requested to implement this
warm-up time not all sites may have done so for all data
collection sessions.
While a relatively heterogeneous group of individuals with
ASD participated in the study, data from more individuals
spanning autism severity and IQ is needed to determine
whether there are meaningfully different profiles. This would
necessarily require a much larger sample than allowed by this
initial observational study. Also, individuals with ASD and
particular symptoms, for instance prominent sensory sensitivities
or inattention, may not have been able to tolerate portions of
JAKE Sense.
Data were generally provided by the primary caregiver. It will
be important to have data from other collateral sources such
as school or program staff and more self-reported data from
individuals with ASD who are capable of providing feedback on
their own cognition, affect, and behavior.
As the primary purpose of the study was to assess the system in
ASD participants, the size of the TD sample was relatively small
in comparison. My JAKE was also not used by the TD cohort.
CONCLUSIONS
JAKE is a dynamic system being developed to identify
subpopulations of individuals with ASD and to sensitively
measure ASD intervention outcomes. The use of JAKE in future
interventional trials has the potential to advance novel treatments
for ASD core and associated symptoms. In this study, JAKE
demonstrated the ability to capture a broad range of high-
quality data on ASD. Interventional studies will be needed to
demonstrate the ability of JAKE to serve as a robust and sensitive
measurement tool.
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